Oxford, UK – 6 June 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, announces that Dr Stuart Naylor will step down from the Board of Oxford BioMedica and as Chief Scientific Officer at the Company’s Annual General Meeting today. In line with the evolution of the Company’s strategy, the role of Chief Scientific Officer has been replaced with the role of Chief Medical Officer and Dr Madhu Davies, who has previously worked as a consultant to Oxford BioMedica, will be appointed to this position as of 7 June 2013.
Oxford BioMedica has evolved from being a primarily research-driven organisation into a more commercially-focused company with increasing emphasis on activities such as clinical development and manufacturing. After 16 years with Oxford BioMedica, Stuart and the Board agree that the time is right for Stuart to seek to apply his skills and expertise to new challenges, and for Oxford BioMedica to apply alternative expertise to support the Company in its next phase of growth.
Dr Madhu Davies MB ChB DRCOG DGM MRCGP FFPM CSci MBA (Cantab) is a medically qualified physician with more than 25 years’ industry experience. Previously, Dr Davies has been responsible for leading the strategic development and management of products from concept through to registration, launch and lifecycle management across multiple therapeutic areas. Dr Davies has also implemented global clinical development programmes from Phase I to III, through to market and has a strong track record of clinical evaluation, product registration and medical marketing both in Europe and the USA.
Nick Rodgers, Chairman of Oxford BioMedica, said: “Having joined as a specialist in cancer biology in 1997, Stuart has played a significant role in the diversification of our research pipeline into CNS and ophthalmology. We are grateful for Stuart’s long-standing contribution to Oxford BioMedica and wish him every success in the future. I would like to welcome Madhu to the management team – as a clinical-stage biopharmaceutical company, Madhu’s role will be key to delivering future commercial success.”
There is no other information to be disclosed under Paragraph 9.6.13 R of the Listing Rules.
Notes to editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tel: +44 (0)1865 783 000
Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton
Tel: +44 (0)20 3709 5700
Peel Hunt (Joint Corporate Brokers):
James Steel/Christopher Golden
Tel: +44 (0)20 7418 8900
WG Partners (Joint Corporate Brokers):
David Wilson/Claes Spang
Tel: +44 (0)20 3705 9321